Health Claims

In HIV patients with belly fat, higher amounts of visceral fat were linked to higher liver enzyme levels at the start of the study.

Correlational

Even after stopping tesamorelin and some fat coming back, the liver enzyme improvements stayed for a year in patients who initially lost visceral fat.

Quantitative

HIV patients with high liver enzymes who lost at least 8% visceral fat after taking tesamorelin saw their ALT drop by about 9 units on average, while those without fat loss had a slight increase, showing a clear benefit from fat reduction.

Quantitative

HIV patients with belly fat who took tesamorelin had a 69% chance of losing at least 8% visceral fat, while those on placebo had only a 33% chance, showing a clear benefit from the drug.

Quantitative

Before starting treatment, people with HIV and fatty liver disease who were taking integrase inhibitors had similar body measurements as those not taking them.

Descriptive

Out of 61 people with HIV and fatty liver disease in the study, 39 were taking integrase inhibitors, and most of those (41% of all participants) were on dolutegravir.

Descriptive

Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.

Descriptive

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

Causal

For people with HIV and fatty liver disease who are taking integrase inhibitor drugs, taking tesamorelin for a year likely helped reduce belly fat, while those on a placebo saw their belly fat increase.

Causal

In people with HIV who have belly fat and are on medication to control the virus, changes in IGF-1 levels from tesamorelin treatment did not relate to changes in thinking skills or waist size. This finding is from the abstract summary - full study details were not available

Correlational

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had higher levels of a growth-related hormone called IGF-1. This finding is from the abstract summary - full study details were not available

Correlational

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin did not show a significant improvement in thinking skills compared to those who received usual care after six months. This finding is from the abstract summary - full study details were not available

Correlational

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had a waist size that was about 2.7 centimeters smaller on average compared to those who didn't, and this difference was statistically significant. This finding is from the abstract summary - full study details were not available

Correlational

Stopping tesamorelin causes the positive effects to go away in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available

Descriptive

Taking tesamorelin makes people with HIV feel better about their belly appearance. This finding is from the abstract summary - full study details were not available

Descriptive

Tesamorelin helps lower blood fat levels in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available

Descriptive

Tesamorelin doesn't significantly change the fat under the skin in people with HIV-related body shape changes. This finding is from the abstract summary - full study details were not available

Descriptive

Taking tesamorelin is linked to less belly fat in people with HIV who have body shape changes. This finding is from the abstract summary - full study details were not available

Descriptive

Adding omentum removal to gastric bypass surgery didn't change levels of hormones produced by fat tissue (adipokines) in women with severe obesity and metabolic syndrome.

Descriptive

Non-diabetic women with severe obesity and metabolic syndrome who had gastric bypass surgery with omentum removal had better overall insulin function (disposition index) at 6 and 12 months compared to those who only had the bypass.

Descriptive

For non-diabetic women with severe obesity and metabolic syndrome who had gastric bypass surgery, adding omentum removal helped maintain their body's insulin response to sugar after one year, while those without it saw a decline.

Descriptive

Women with severe obesity and metabolic syndrome who had gastric bypass surgery with omentum removal had lower levels of a marker for inflammation (CRP) after one year compared to those who only had the bypass.

Descriptive

For women with severe obesity and metabolic syndrome who had gastric bypass surgery, adding the removal of the omentum fat led to more weight loss over time compared to just the bypass alone.

Descriptive

In people with HIV and belly fat, the amount of visceral fat didn't correlate with liver enzyme AST levels when other factors like sex and hepatitis were considered.

Correlational